kidney/RAAS

Every compound in the sci-wiki that affects kidney/raas; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

2 sourced · 0 reference

←kidney/raas2/2

ARB

Olmesartan Medoxomil

Olmesartan medoxomil is an orally active angiotensin II receptor blocker (ARB) used to treat high blood pressure in adults and children. It is the prodrug form of olmesartan, meaning it is absorbed as an inactive medoxomil ester and then rapidly converted in the body to the active compound, which selectively blocks the angiotensin II type 1 (AT1) receptor. Developed by Sankyo, now Daiichi Sankyo, and co-marketed in some regions with Merck, it was patented in the early 1990s and reached medical use in 2002, and it is sold under brand names such as Benicar and Olmetec.

1 outlet

Blend

Olmesartan Medoxomil + Azelnidipine

Olmesartan medoxomil plus azelnidipine is a fixed-dose antihypertensive tablet that combines an angiotensin II receptor blocker with a dihydropyridine calcium channel blocker. Marketed chiefly in Japan under the brand name Rezaltas, it pairs olmesartan, which relaxes blood vessels by blocking the AT1 receptor, with azelnidipine, a calcium channel blocker noted for its gradual onset and minimal effect on heart rate. The single-pill format is used to control blood pressure in patients for whom one drug is not enough, delivering two complementary agents in one daily tablet.

1 outlet